

## (12) United States Patent Palmaz

# (10) Patent No.: US 7,300,457 B2 (45) Date of Patent: \*Nov. 27, 2007

- (54) SELF-SUPPORTING METALLIC IMPLANTABLE GRAFTS, COMPLIANT IMPLANTABLE MEDICAL DEVICES AND METHODS OF MAKING SAME
- (75) Inventor: Julio C. Palmaz, San Antonio, TX (US)
- (73) Assignee: Advanced Bio Prosthetic Surfaces,

Ltd., San Antonio, TX (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 238 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 10/135,316
- (22) Filed: Apr. 29, 2002
- (65) Prior Publication Data
   US 2007/0250156 A1 Oct. 25, 2007

### **Related U.S. Application Data**

(63) Continuation-in-part of application No. 09/532,164, filed on Mar. 20, 2000, now Pat. No. 6,537,310, and a continuation-in-part of application No. 09/443,929, filed on Nov. 19, 1999, now Pat. No. 6,379,383.

### (Continued)

### OTHER PUBLICATIONS

"Liquid Sources for Chemical Vapor Deposition of Group 6 Metals and Metal Nitrides" by Gordon, et al., www.techtransfer.harvard. edu/cgi-bin/TALSearch.cgi?full\_report=1&case=3, Case No. 1709.

### (Continued)

Primary Examiner—Kevin T. Truong
(74) Attorney, Agent, or Firm—Rosenbaum & Associates,
PC; David G. Rosenbaum; J. Peter Paredes

(57) **ABSTRACT** 

Implantable medical grafts fabricated of metallic or pseudometallic films of biocompatible materials having a plurality of microperforations passing through the film in a pattern that imparts fabric-like qualities to the graft or permits the geometric deformation of the graft. The implantable graft is preferably fabricated by vacuum deposition of metallic and/or pseudometallic materials into either single or multilayered structures with the plurality of microperforations either being formed during deposition or after deposition by selective removal of sections of the deposited film. The implantable medical grafts are suitable for use as endoluminal or surgical grafts and may be used as vascular grafts, stent-grafts, skin grafts, shunts, bone grafts, surgical patches, non-vascular conduits, valvular leaflets, filters, occlusion membranes, artificial sphincters, tendons and ligaments.

- (60) Provisional application No. 60/302,797, filed on Jul.3, 2001.

See application file for complete search history.

### 18 Claims, 6 Drawing Sheets



# **US 7,300,457 B2** Page 2

### U.S. PATENT DOCUMENTS

4,510,182 4,657,544				
/ /	Α	4/1985	Cornils et al 427/162	
			Pinchuk 623/1	
· · ·				
4,751,099	А	6/1988	Niino et al 427/34	
4,846,834	Α	7/1989	von Recum et al 623/11	
5,049,251	Δ	9/1991	Inoue	
/ /			Busch et al	
5,061,914				
5,078,736	Α	1/1992	Behl 623/1	
5,084,151	Α	1/1992	Vallana 204/192.11	
5,133,845			Vallana et al 204/192	
· · ·				
5,207,709			Picha 623/11	
5,242,710	Α	9/1993	Claar et al 427/248	
5.277.933	А	1/1994	Claar et al 427/248	
5,370,684			Vallana et al 623/1	
/ /				
5,387,247		2/1995	Vallana et al 623/2	
5,421,955	Α	6/1995	Lau et al 216/48	
5,455,100	Α	10/1995	White 428/131	
5,477,864			Davidson 128/771	
/ /				
5,514,154			Lau et al 606/195	
5,540,820	Α	7/1996	Terakado et al 204/192.3	
5,545,210	Α	8/1996	Hess et al 623/1	
5,569,295			Lam	
/ /				
· · ·			Parodi 623/1.13	
5,593,442	А	1/1997	Klein 623/12	
5,603,721	Α	2/1997	Lau et al 606/195	
5,605,714			Dearnaley et al 427/2.24	
/ /			-	
5,607,445			Summers 606/198	
5,607,463	Α	3/1997	Schwartz et al 623/1	
5,609,629	А	3/1997	Fearnot et al 623/1	
5,628,788			Pinchuk 623/1	
/ /				
5,630,840			Mayer 623/1	
5,632,779	Α	* 5/1997	Davidson 623/1.51	
5,647,858	Α	7/1997	Davidson 604/264	
5,649,951	Α		Davidson 606/198	
/ /				
			Campbell 623/1	
5,656,036	Α	8/1997	Palmaz 623/12	
5,683,453	Α	11/1997	Palmaz 623/1	
5.685.961	А	11/1997	Pourrezaei et al 204/192	
/ /			Davidson	
· · ·				
5,723,004			Dereume et al 623/1.35	
5,723,219	А	3/1998	Kolluri 428/411.1	
5,725,573	Α	3/1998	Dearnaley et al 623/2	
5,728,150			McDonald et al 623/1.15	
5,720,150	$\mathbf{T}$	5/1770		
5 700 150	*	2/1000	1 - 1 - 1 - (2)	
5,728,158			Lau et al 623/12	
5,728,158 5,733,303			Lau et al 623/12 Israel et al 606/198	
5,733,303	Α	3/1998	Israel et al 606/198	
5,733,303 5,735,896	A A	3/1998 4/1998	Israel et al 606/198 Amon et al 623/11	
5,733,303 5,735,896 5,744,515	A A A	3/1998 4/1998 4/1998	Israel et al 606/198 Amon et al 623/11 Clapper 523/113	
5,733,303 5,735,896 5,744,515 5,765,418	A A A	3/1998 4/1998 4/1998 6/1998	Israel et al	
5,733,303 5,735,896 5,744,515	A A A	3/1998 4/1998 4/1998 6/1998	Israel et al 606/198 Amon et al 623/11 Clapper 523/113	
5,733,303 5,735,896 5,744,515 5,765,418	A A A A	3/1998 4/1998 4/1998 6/1998 6/1998	Israel et al	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161	A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807	A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908	A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,775,161 5,780,807 5,782,908 5,782,910	A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908	A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,775,161 5,780,807 5,782,908 5,782,910	A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,910 5,788,558 5,7811,151	A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 8/1998 9/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,788,558 5,811,151 5,824,045	A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,788,558 5,811,151 5,824,045 5,824,049	A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 9/1998 9/1998 10/1998 10/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,788,558 5,811,151 5,824,045 5,824,045 5,824,049 5,824,056	A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1         Rosenberg       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,788,558 5,811,151 5,824,045 5,824,049	A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,782,910 5,788,558 5,788,558 5,811,151 5,824,045 5,824,045 5,824,049 5,824,056	A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1         Rosenberg       623/1         Fischell et al.       600/3	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,049 5,840,009 5,843,117	A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 11/1998 12/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1         Fischell et al.       600/3         Alt et al.       606/194	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,049 5,824,056 5,843,117 5,843,120	A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 11/1998 12/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Rosenberg       623/1         Ragheb       623/1         Fischell et al.       600/3         Alt et al.       606/194         Israel et al.       606/198	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,843,117 5,843,120 5,843,289	A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 11/1998 12/1998 12/1998	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Fischell et al. $600/3$ Alt et al. $606/194$ Israel et al. $606/198$ Lee et al. $204/192$	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,843,120 5,843,120 5,843,289 5,849,206	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 11/1998 12/1998 12/1998 12/1998	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Rosenberg $623/1$ Fischell et al. $600/3$ Alt et al. $606/194$ Israel et al. $606/194$ Lee et al. $204/192$ Amon et al. $216/63$	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,843,117 5,843,120 5,843,289	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 11/1998 12/1998 12/1998 12/1998	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Fischell et al. $600/3$ Alt et al. $606/194$ Israel et al. $606/198$ Lee et al. $204/192$	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,049 5,824,049 5,824,056 5,843,120 5,843,120 5,843,289 5,849,206 5,855,600	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Rosenberg       623/1         Ragheb       623/1         Rosenberg       623/1         Ragheb       623/1         Rischell et al.       600/3         Alt et al.       606/194         Israel et al.       204/192         Amon et al.       216/63         Alt       623/1	
5,733,303 5,735,896 5,744,515 5,765,418 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,049 5,843,117 5,843,120 5,843,289 5,849,206 5,855,600 5,855,802	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Rosenberg $623/1$ Fischell et al. $606/194$ Israel et al. $606/194$ Israel et al. $204/192$ Amon et al. $216/63$ Alt $623/1$ Acciai et al. $216/8$	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,049 5,824,049 5,843,117 5,843,120 5,843,120 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,855,600 5,855,802 5,855,955	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Rosenberg       623/1         Ragheb       623/1         Rosenberg       623/1         Rischell et al.       600/3         Alt et al.       606/194         Israel et al.       204/192         Amon et al.       216/63         Alt       623/1         Rosenberg       623/1         Rosenberg       623/1         Rosenberg       623/1         Saule et al.       606/194         Israel et al.       606/198         Lee et al.       204/192         Amon et al.       216/63         Alt       623/1         Acciai et al.       216/8         Claar et al.       216/8	
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,843,117 5,843,120 5,843,120 5,843,120 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Rosenberg $623/1$ Fischell et al. $606/194$ Israel et al. $606/194$ Israel et al. $204/192$ Amon et al. $216/63$ Alt $623/1$ Acciai et al. $216/8$ Claar et al. $216/8$ Claar et al. $427/248.1$ Eckert et al. $428/586$	20
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,049 5,824,049 5,843,117 5,843,120 5,843,120 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,855,600 5,855,802 5,855,955	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Rosenberg       623/1         Ragheb       623/1         Rosenberg       623/1         Rischell et al.       600/3         Alt et al.       606/194         Israel et al.       204/192         Amon et al.       216/63         Alt       623/1         Rosenberg       623/1         Rosenberg       623/1         Rosenberg       623/1         Saule et al.       606/194         Israel et al.       606/198         Lee et al.       204/192         Amon et al.       216/63         Alt       623/1         Acciai et al.       216/8         Claar et al.       216/8	20 20
5,733,303 5,735,896 5,744,515 5,765,418 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,843,117 5,843,120 5,843,120 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,285 5,855,600 5,855,600 5,855,955 5,855,955 5,858,556 5,858,556 5,866,113	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1999 1/1999 1/1999 1/1999 1/1999	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Rosenberg $623/1$ Rosenberg $623/1$ Fischell et al. $606/194$ Israel et al. $606/194$ Israel et al. $204/192$ Amon et al. $216/63$ Alt $623/1$ Acciai et al. $216/8$ Claar et al. $216/8$ Claar et al. $427/248.1$ Eckert et al. $424/78.17$	20
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,049 5,824,045 5,843,120 5,843,120 5,843,120 5,843,289 5,855,600 5,855,802 5,855,955 5,858,556 5,866,113 5,868,782	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1999 1/1999 1/1999 1/1999 2/1999	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1         Rosenberg       623/1         Rosenberg       623/1         Ragheb       623/1         Rischell et al.       606/194         Israel et al.       606/194         Israel et al.       606/194         Israel et al.       204/192         Amon et al.       216/63         Alt       623/1         Acciai et al.       216/8         Claar et al.       216/8         Claar et al.       427/248.1         Eckert et al.       428/586         Hendricks et al.       424/78.17         Frantzen       606/198	20 20
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,855,600 5,855,600 5,855,600 5,855,955 5,858,556 5,858,556 5,866,113 5,868,782 5,873,904	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1999 1/1999 1/1999 1/1999 2/1999 2/1999	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Rosenberg $623/1$ Rischell et al. $606/194$ Israel et al. $606/194$ Lee et al. $204/192$ Amon et al. $216/63$ Alt $623/1$ Acciai et al. $216/8$ Claar et al. $216/8$ Claar et al. $427/248.1$ Eckert et al. $424/78.17$ Frantzen $606/198$ Ragheb et al. $623/1$	20 20 20
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,289 5,855,600 5,855,802 5,855,955 5,855,955 5,858,556 5,858,556 5,866,113 5,873,904 5,876,432	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1999 1/1999 1/1999 1/1999 2/1999 2/1999	Israel et al.       606/198         Amon et al.       623/11         Clapper       523/113         Rosenberg       72/47         Moller et al.       205/73         Globerman       606/194         Saunders       219/121         Cahalan et al.       623/1         Davidson       623/3         Klein       451/136         Hendricks et al.       427/2.24         Alt       623/1         Ragheb       623/1         Rosenberg       623/1         Rosenberg       623/1         Ragheb       623/1         Rischell et al.       606/194         Israel et al.       606/194         Israel et al.       606/194         Israel et al.       204/192         Amon et al.       216/63         Alt       623/1         Acciai et al.       216/8         Claar et al.       216/8         Claar et al.       427/248.1         Eckert et al.       428/586         Hendricks et al.       424/78.17         Frantzen       606/198	20 20
5,733,303 5,735,896 5,744,515 5,765,418 5,772,864 5,776,161 5,780,807 5,782,908 5,782,908 5,782,910 5,788,558 5,811,151 5,824,045 5,824,045 5,824,045 5,824,045 5,824,045 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,120 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,843,289 5,855,600 5,855,600 5,855,600 5,855,955 5,858,556 5,858,556 5,866,113 5,868,782 5,873,904	A A A A A A A A A A A A A A A A A A A	3/1998 4/1998 4/1998 6/1998 6/1998 7/1998 7/1998 7/1998 7/1998 8/1998 9/1998 10/1998 10/1998 10/1998 10/1998 10/1998 10/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1998 12/1999 1/1999 1/1999 1/1999 2/1999 2/1999 2/1999	Israel et al. $606/198$ Amon et al. $623/11$ Clapper $523/113$ Rosenberg $72/47$ Moller et al. $205/73$ Globerman $606/194$ Saunders $219/121$ Cahalan et al. $623/1$ Davidson $623/3$ Klein $451/136$ Hendricks et al. $427/2.24$ Alt $623/1$ Ragheb $623/1$ Rosenberg $623/1$ Rischell et al. $606/194$ Israel et al. $606/194$ Lee et al. $204/192$ Amon et al. $216/63$ Alt $623/1$ Acciai et al. $216/8$ Claar et al. $216/8$ Claar et al. $427/248.1$ Eckert et al. $424/78.17$ Frantzen $606/198$ Ragheb et al. $623/1$	20 20 20

5,891,507	А	4/1999	Jayaraman 427/2.25
5,895,406	А		Gray et al 606/198
5,899,935	Α	5/1999	Ding 623/1
5,907,893	Α	6/1999	Zadno-Azizi 29/6.1
5,913,896	А	6/1999	Boyle et al 623/1
5,919,225		7/1999	Lau et al 623/1
5,925,063			Khosravi 606/200
5,932,299			Katoot 427/508
5,938,682			Hojeibane et al 606/198
5,938,697			Killion et al 623/1
5,945,153			Dearnaley 427/2.12
5,951,881			Rogers et al
5,955,588			Tsang et al
5,962,138			Kolluri et al
5,968,091 5,972,018			Pinchuk et al
5,972,018			Israel et al 606/198 Johnson 623/1
5,984,905			Dearnaley et al $604/265$
6,007,573			Wallace et al
6,013,054			Jiun Yan
6,013,855			McPherson et al. $\dots$ 623/11
6,015,429			Lau et al
6,019,784			Hines 623/1
6,022,370			Tower 606/194
6,027,526			Limon et al 623/1
6,033,433		3/2000	Ehr et al 623/1
6,042,597	Α	3/2000	Kveen et al 606/198
6,042,605	А	3/2000	Martin et al 623/1
6,056,776	А	5/2000	Lau et al 623/1
6,059,808			Boussignac et al 606/191
6,066,167			Lau et al 623/1
6,066,168			Lau et al 623/1
6,066,169			McGuiness 623/1.16
6,071,305			Brown et al $623/1$
6,086,773			Dufresne et al
6,096,175			Roth
6,103,320			Matsumoto et al $427/535$
6,106,642 6,113,750			DiCarlo et al 148/563 Shinmura et al 204/192.15
6,120,536			Ding et al. $\dots$ 623/11.43
6,120,847			Yang et al. $$
6,124,523			Banas et al
6,126,793			Sugiyama et al 204/192.23
6,136,258			Wang et al 264/514
6,190,404	B1	2/2001	Palmaz et al 623/1.15
6,202,304	B1	3/2001	Shatz 29/896.6
6,207,536	B1	3/2001	Matsumoto et al 438/478
6,240,616	B1	6/2001	Yan 29/527.2
6,245,104		6/2001	Alt 623/1.46
6,264,687		7/2001	Tomonto 623/1.16
6,274,014		8/2001	Matsumoto et al 204/298.11
6,280,467			Leonhardt 623/1.16
6,287,277			Yan
6,287,329			Duerig et al
6,287,435 6,287,628			Drewery et al 204/298.09 Hossainy et al 427/2.3
6,290,720			Khosravi et al. $\dots 623/1.13$
6,290,720		9/2001	Heath
6,293,967		9/2001	Shanley 623/1.15
6,299,604			Ragheb et al 604/265
6,312,463			Rourke et al
6,315,708			Salmon et al
6,315,794		11/2001	Richter
6,331,191		12/2001	Chobotov 623/1.44
6,428,569			Brown 623/1.15
6,458,152	B1	10/2002	Khosravi et al 623/1.13
6,936,066	B2 *	8/2005	Palmaz et al 623/1.13
2001/0000188	Al	4/2001	Lenker et al.
2001/0019847			Ori et al.
2001/0021870			Edwin et al.
2001/0025131			Edwin et al.
2001/0032013		10/2001	
2001/0037144	Al	11/2001	Kım et al.

### Page 3

2001/0039449 A1	11/2001	Johnson et al.
2002/0013616 A1	1/2002	Carter et al.

### FOREIGN PATENT DOCUMENTS

	JP	61-88135	7/1994
-	WO	97/44692	11/1997
-	WO	98/13537	4/1998
-	WO	98/45506	10/1998
-	WO	99/16385	4/1999
-	WO	99/23977	5/1999
-	WO	00/04204	1/2000
-	WO	00/18327	4/2000
-	WO	00/54704	9/2000
-	WO	00/071054	11/2000
-	WO	00/71054	11/2000
-	WO	01/21851	3/2001
-	WO	01/21852	3/2001
-	WO	01/37892	5/2001
-	WO	01/43790	6/2001
-	WO	01/49340	7/2001
-	WO	01/53559	7/2001
-	WO	01/55473	8/2001

"PHYTIS L.D.A. Home Page information", http://www.phytis.com/ content/htm, pp. 1-15.

"Risk Analysis of Stents With a Diamond-Like Coated Surface For Use in Prosthetic Implants", http://www.phytis.com/risk.htm, pp. 1-6.

"Directions for Use, DIAMOND AS® Stent", http://www.phytis. com/direcuse.htm, pp. 1-8.

"Stents: Literature", http://www.phytis.com/liter.htm, pp. 1-8. "The Effects of Ion Irradiation on NiTi Shape Memory Alloy Thin Films" by F. Goldberg and E. Knystautas, *Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA*, pp. 177-182 (1997).

"Constitutive Parts of a Shape Memory Allloy Titanium Nickel Thin Film Catheter" by L. Buchaillot, et al., *Proceedings of the Second* International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 183-188 (1997). "The Effect of HCD Technological Factors on the NiTi SMA Film Thickness" by Q. Pingshan, et al., Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 173-176 (1997). "Microstructure of Ti-Rich TiNi Thin Films" by A. Ishida, et al., Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA, pp. 161-166 (1997). "Thin Film Shape Memory Alloy Microactuators" by TiNi Alloy Company (online). "Progress in Thin Film Shape Memory Microactuators" by Johnson, et al., www.sma-mems.com/recent.htm (Overview), pp. 1-5. "A Concise History of Vacuum Coating Technology, Part 2: 1940 to 1975" by D. Mattox, www.svc.org/HistoryofVac2.html, pp. 1-15. "Model Surfaces for Studying and Controlling the Adhesion of Cells" by M. Mrksich, AVS 47<sup>th</sup> International Symposium, Invited Paper No. BI+EL-TuA1 (Oct. 3, 2000).

### OTHER PUBLICATIONS

"Fabrication of Small-Scale Coils and Bands as Photomasks on Optical Fibers for Generation of In-Fiber Gratings, Electromagnets as Micro-NMR Coils, Microtransformers, and Intra-Vascular Stents" www.techtransfer.harvard.edu/cgi-bin/TALSearch. cgi?full\_report=1&case=72, Case No. 1263.

"Reactions of Biological Cells to Nanostructures", by Curtis, et al., AVS 46<sup>th</sup> International Symposium, Paper BI-WeM2 (Oct. 27, 1999).

"Biocompatibility of Cardiac Cells on Silane-Modified Surfaces" AVS 46<sup>th</sup> International Symposium, Paper BI-WeM5 (Oct. 27, 1999).

"Biofunctionalization of Surfaces with Peptide Amphilphiles" AVS 46<sup>th</sup> International Symposium, Paper No. BI-WeM7 (Oct. 27, 1999). "Plasma Copolymer Surfaces for Cell Culture" AVS 46th International Symposium, Paper No. PaperBI-WeM9 (Oct. 27, 1999). "Plasma Co-polymer Surfaces for the Controlled Adsorption of Common Proteins" AVS 46<sup>th</sup> International Symposium, Paper No. BI-FrM2 (Oct. 29, 1999). "Biofilm—Titanium Chemistry for Adhesion Using X-ray Photoelectron Spectroscopy" AVS 46<sup>th</sup> International Symposium, Paper No. BI-FrM8. "Nanoscale Pattering of Gold for Attachment of Supported Lipid Bilayers" AVS 46<sup>th</sup> International Symposium, Paper No. BI-Frm10. "Focused Ion Beam Non-Fabrication", http://www.glue.umd. edu/~astan/avs04.htm."Amorphous Carbon and C:N Thin Films" http://www.glue.umd. edu/~astan/avs01.htm. Multilayer Ceramic/Metallic Coatings by Ion Beam-Assisted, Electron Beam Physical Vapor (EB-PVD) Deposition, Penn State Applied Research Laboratory, pp. 1-4 (1997). "Benefits From Diamond-Like Coated Stainless Steel Stents", http:// www.phytis.com/stens0.1htm, pp. 1-2. "Adhesion of Bovine Serum Albumin on Coated DLC (Diamond-Like) and Uncoated (SiO<sub>2</sub> / TiO<sub>2</sub>) Sensor Chips", http://www.phytis. com/stent4.htm, pp. 1-2.

"Cell Response to Chemically and Topographically Modified Surfaces" by D.S. Sutherland, et al., AVS 47<sup>th</sup> International Symposium, Paper No. BI+EL-TuA3 (Oct. 3, 2000). "The Nanomechanical Properties of Thin Films" by J.E. Houston, AVS 47<sup>th</sup> International Symposium, Paper No. TF-TuA1 (Oct. 3, 2000).

"Flow Cytometric Investigation", http://www.phytis.com/stent6. htm, pp. 1-3. "Pre-clinical and Clinical Evaluation", http://www.phytis.com/ stent2.htm, pp. 1B2. "Anomalous Plastic and Elastic Behaviors of Suptrer-deposited TiNi with 10 or 20 Inserted Thin A1 Layers Evaluated by Nanoindentation" by E. Kusano, et al., AVS 47<sup>th</sup> International Symposium, Paper No. TF-TuA3 (Oct. 3, 2000).

"Recent Progress in the Application of Thin Film Shape Memory Alloys" by A.D. Johnson and J.D. Busch, *Proceedings of the First International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA*, pp. 299-310 (1994).

"Thin-film Processing of TiNi Shape Memory Alloy" by J.A. Waker and K.J. Gabriel, *Sensors and Actuators*, A21-A23, pp. 243-246 (1990).

"Sputter-deposition of TiNi, TiNiPd and TiPd films displaying the two-way shape-memory effect" by E. Quandt, et al., *Sensors and Actuators*, A 53, pp. 434-439 (1996).

"Applications of Shape-Memory Alloy Thin Films" by A.D. Johnson and V.V. Martynov, *Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA*, pp. 1-8 (1997).

"The New Phytis Stent", http://www.phytis.com/stent1.htm, pp. 1-2.

"Invulnerability and Resistance of DLC-Coating", http://www.phytis.com/stent3.htm, pp. 1-3.

"Material In Use and Its Biocompatibility", http://www.phytis.com/ stent5.htm, pp. 1-2.

"Expertise Concerning the Implementation of the PHYTIS DIA-MOND AS STENT Performed at the Institute for Experimental Medicine (IEM)", http://www.phytis.com/stent9.htm, pp. 1. "The Characteristics of NiTiHCD-Deposited SMA Films" by H. Weixin, et al., *Proceedings of the Second International Conference on Shape Memory and Superelastic Technologies Asilomar Conference Center, Pacific Grove, California, USA*, pp. 167-172 (1997). "The influence of ion irradiation during film growth on the chemical stability of film/substrate systems" by W. Ensinger, *Surface and Coatings Technology*, vol. 80, pp. 35-48 (1996). "Sputtering Targets High-Quality Thin Film Materials " by AMETEK Specialty Metal Products online at www.ametek84.com/ fd-sputtering.html, pp. 1-3.

### **US 7,300,457 B2** Page 4

- "Tissue Formation of Hepatocytes on Micro-Porous Films of Polylactide" by T. Nishikawa, et al., AVS 47<sup>th</sup> International Symposium, Paper No. BI+EL-TuA10 (Oct. 3, 2000).
- "Endothelial Cell Organization on Micropatterned Protein Surfaces" by R. Daw, et al., AVS 47<sup>th</sup> International Symposium, Paper No. BI-WeP21 (Oct. 4, 2000).
- "Shape Memory Properties in NiTi Sputter-deposited Film", by J.D. Busch and A.D. Johnson, *J Appl. Phys*, vol. 68, No. 12, pp. 6224-6226 (Dec. 15, 1990).
- "Multicomponent Film Deposition by Target Baising", *IBM Technical Disclosure Bulletin*, pp. 1-2 (Jul. 1980).
- "The Experimental Use of Steel Mesh Tubes for the Replacement of Arterial Segments," by Larry, Banning G., M.D., et al, *Presented at* the Third Scientific Meeting of the North American Chapter of the

Abstract: "Vacuum conditions for sputtering thin film TiNi" by A. Peter Jardine, *Journal of Vacuum Science & Technology A: Vacuum, Surfaces, and Films*, May 1995, vol. 13, Issue 3, pp. 1058-1062.

Abstract: "Oriented nickel-titanium shape memory alloy films prepared by annealing during deposition" by K. Gisser, J. Bussh and A. Johnson and A. Ellis, *Applied Physics Letters*, Oct. 1992, vol. 61, Issue 14, pp. 1632-1634.

Abstract: "Relative importance of bombardment energy and intensity in ion plating" by K.S. Fancey, C.A. Porter and A. Matthews, *Journal of Vacuum Science & Technology A: Vacuum, Surfaces, and Films*, Mar. 1995, vol. 13, Issue s, pp. 428-435.

the Third Scientific Meeting of the North American Chapter of the International Society of Angiology, Atlantic City, N.J., pp. 69-75, Jun. 4, 1955.

\* cited by examiner

# U.S. Patent Nov. 27, 2007 Sheet 1 of 6 US 7,300,457 B2







## U.S. Patent Nov. 27, 2007 Sheet 2 of 6 US 7,300,457 B2



# U.S. Patent Nov. 27, 2007 Sheet 3 of 6 US 7,300,457 B2



Fig. 3A





# U.S. Patent Nov. 27, 2007 Sheet 4 of 6 US 7,300,457 B2



Fig. 6





# U.S. Patent Nov. 27, 2007 Sheet 5 of 6 US 7,300,457 B2



Fig. 8A





# U.S. Patent Nov. 27, 2007 Sheet 6 of 6 US 7,300,457 B2







Fig. 10B

### **SELF-SUPPORTING METALLIC IMPLANTABLE GRAFTS, COMPLIANT IMPLANTABLE MEDICAL DEVICES AND METHODS OF MAKING SAME**

### CROSS REFERENCE TO RELATED APPLICATIONS

The present application corresponds to and claims priority to provisional patent application U.S. Ser. No. 60/302,797, 10 filed Jul. 3, 2001 and is a continuation in part of commonly assigned U.S. patent application Ser. No. 09/443,929, filed Nov. 19, 1999 now U.S. Pat. No. 6,379,383 and Ser. No. 09/532,164 filed Mar. 20, 2000 now U.S. Pat. No. 6,537,310.

cellular binding to the prosthetic surface may occur by integrin-ligand docking. It has also been observed that proteins bind to metals in a more permanent fashion than they do to polymers, thereby providing a more stable adhe-5 sive surface. The conformation of proteins coupled to surfaces of most medical metals and alloys appears to expose greater numbers of ligands and preferentially attract endothelial cells having surface integrin clusters to the metal or alloy surface relative to leukocytes. Finally, metals and metal alloys exhibit greater resistance to degradation of metals relative to polymers, thereby providing greater longterm structural integrity and stable interface conditions.

Because of their relatively greater adhesive surface profiles, metals are also susceptible to short-term platelet activ-15 ity and/or thrombogenicity. These deleterious properties may be offset by administration of pharmacologically active antithrombogenic agents in routine use today. Surface thrombogenicity usually disappears 1-3 weeks after initial exposure. Antithrombotic coverage is routinely provided during this period of time for coronary stenting. In nonvascular applications such as musculoskeletal and dental, metals have also greater tissue compatibility than polymers because of similar molecular considerations. The best article to demonstrate the fact that all polymers are inferior to metals is van der Giessen, W J. et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries, Circulation, 1996:94(7):1690-7. Normally, endothelial cells (EC) migrate and proliferate to cover denuded areas until confluence is achieved. Migra-30 tion, quantitatively more important than proliferation, proceeds under normal blood flow roughly at a rate of 25 µm/hr or 2.5 times the diameter of an EC, which is nominally 10 μm. EC migrate by a rolling motion of the cell membrane, coordinated by a complex system of intracellular filaments attached to clusters of cell membrane integrin receptors, specifically focal contact points. The integrins within the focal contact sites are expressed according to complex signaling mechanisms and eventually couple to specific amino acid sequences in substrate adhesion molecules. An EC has roughly 16-22% of its cell surface represented by integrin clusters. Davies, P. F., Robotewskyi A., Griem M. L. Endothelial cell adhesion in real time. J. Clin. Invest. 1993; 91:2640-2652, Davies, P. F., Robotewski, A., Griem, M. L., Qualitative studies of endothelial cell adhesion, J. Clin. Invest. 1994; 93:2031-2038. This is a dynamic process, which implies more than 50% remodeling in 30 minutes. The focal adhesion contacts vary in size and distribution, but 80% of them measure less than 6  $\mu$ m<sup>2</sup>, with the majority of them being about 1  $\mu$ m<sup>2</sup>, and tend to elongate in the direction of flow and concentrate at leading edges of the cell. Although the process of recognition and signaling to determine specific attachment receptor response to attachment sites is incompletely understood, availability of attachment sites will favorably influence attachment and migration. It is known that materials commonly used as medical grafts, such as polymers, do not become covered with EC and therefore do not heal after they are placed in the arteries. It is therefore an object of this invention to replace polymer grafts with When implanted into the body, metals are generally 60 metal grafts that can potentially become covered with EC and can heal completely. Furthermore, heterogeneities of materials in contact with blood flow are preferably controlled by using vacuum deposited materials. There have been numerous attempts to increase endothelialization of implanted medical devices such as stents, including covering the stent with a polymeric material (U.S. Pat. No. 5,897,911), imparting a diamond-like carbon coat-

### BACKGROUND OF THE INVENTION

The present invention relates generally to implantable metallic medical devices. More specifically, the present invention relates to implantable medical devices, including, 20 for example, surgical and endoluminal vascular grafts, stent grafts, skin grafts, shunts, bone grafts, surgical patches, non-vascular conduits, valvular leaflets, filters, occlusion membranes, sphincters, artificial tendons and ligaments. More specifically, the present invention relates to implantable medical grafts fabricated of metallic or pseudometallic films of biocompatible materials having a plurality of microperforations passing through the film. The plurality of microperforations may serve multiple purposes, including, for example, permitting geometric deformation of the film, imparting a fabric-like quality to the film, and imparting flexibility to the film. The term "fabric-like" is intended to mean a quality of being pliable and/or compliant in a manner similar to that found with natural or synthetic woven fabrics. The inventive implantable grafts are fabricated entirely of 35 self-supporting films made of biocompatible metals or biocompatible pseudometals. Heretofore in the field of implantable medical devices, it is unknown to fabricate an implantable medical device that comprises a graft at least as one of its elements, such as a stent graft, entirely of self-supporting 40 metal or pseudometal materials. As used herein the term "graft" is intended to indicate any type of device or part of a device that comprises essentially a material delimited by two surfaces where the distance between said surfaces is the thickness of the graft and that exhibits integral dimensional 45 strength and that has microperforations that pass through the thickness of the graft. The inventive grafts may be formed in planar sheets, toroids, and in other shapes as particular applications may warrant. However, for purposes of illustration only, the present application will refer to tubular 50 grafts. For purposes of this application, the terms "pseudometal" and "pseudometallic" are intended to mean a biocompatible material which exhibits biological response and material characteristics substantially the same as biocompatible metals. Examples of pseudometallic materials 55 include, for example, composite materials and ceramics. Composite materials are composed of a matrix material reinforced with any of a variety of fibers made from ceramics, metals, carbon, or polymers. considered to have superior biocompatibility than that exhibited by polymers used to fabricate commercially available polymeric grafts. It has been found that when prosthetic materials are implanted, integrin receptors on cell surfaces interact with the prosthetic surface. The integrin receptors 65 are specific for certain ligands in vivo. If a specific protein is adsorbed on a prosthetic surface and the ligand exposed,

ing onto the stent (U.S. Pat. No. 5,725,573), covalently binding hydrophobic moieties to a heparin molecule (U.S. Pat. No. 5,955,588), coating a stent with a layer of blue to black zirconium oxide or zirconium nitride (U.S. Pat. No. 5,649,951), coating a stent with a layer of turbostratic carbon 5 (U.S. Pat. No. 5,387,247), coating the tissue-contacting surface of a stent with a thin layer of a Group VB metal (U.S.) Pat. No. 5,607,463), imparting a porous coating of titanium or of a titanium alloy, such as Ti—Nb—Zr alloy, onto the surface of a stent (U.S. Pat. No. 5,690,670), coating the 10 stent, under ultrasonic conditions, with a synthetic or biological, active or inactive agent, such as heparin, endothelium derived growth factor, vascular growth factors, silicone, polyurethane, or polytetrafluoroethylene, U.S. Pat. No. 5,891,507), coating a stent with a silane compound with 15 ported by a homogeneous distribution of binding domains vinyl functionality, then forming a graft polymer by polymerization with the vinyl groups of the silane compound (U.S. Pat. No. 5,782,908), grafting monomers, oligomers or polymers onto the surface of a stent using infrared radiation, microwave radiation or high voltage polymerization to 20 impart the property of the monomer, oligomer or polymer to the stent (U.S. Pat. No. 5,932,299). However, all these approaches do not address the lack of endothelialization of polymer grafts. It is, therefore, desirable to fabricate the inventive graft of 25 metallic and/or pseudometallic materials. The inventive metal devices may be fabricated of pre-existing conventional wrought metallic materials, such as stainless steel or nitinol hypotubes, or may be fabricated by thin film vacuum deposition techniques. In accordance with the present inven- 30 tion, it is preferable to fabricate the inventive implantable devices by vacuum deposition. Vacuum deposition permits greater control over many material characteristics and properties of the resulting formed device. For example, vacuum deposition permits control over grain size, grain phase, grain 35 material composition, bulk material composition, surface topography, mechanical properties, such as transition temperatures in the case of a shape memory alloy. Moreover, vacuum deposition processes will permit creation of devices with greater material purity without the introduction of large 40 quantities of contaminants that adversely affect the material, mechanical or biological properties of the implanted device. Vacuum deposition techniques also lend themselves to fabrication of more complex devices than those susceptible of manufacture by conventional cold-working techniques. For 45 example, multi-layer structures, complex geometrical configurations, extremely fine control over material tolerances, such as thickness or surface uniformity, are all advantages of vacuum deposition processing. In vacuum deposition technologies, materials are formed 50 directly in the desired geometry, e.g., planar, tubular, etc. The common principle of vacuum deposition processes is to take a material in a minimally processed form, such as pellets or thick foils, known as the source material and atomize them. Atomization may be carried out using heat, as 55 is the case in physical vapor deposition, or using the effect of collisional processes, as in the case of sputter deposition, for example. In some forms of deposition, a process, such as laser ablation, which creates microparticles that typically consist of one or more atoms, may replace atomization; the 60 number of atoms per particle may be in the thousands or more. The atoms or particles of the source material are then deposited on a substrate or mandrel to directly form the desired object. In other deposition methodologies, chemical reactions between ambient gas introduced into the vacuum 65 chamber, i.e., the gas source, and the deposited atoms and/or particles are part of the deposition process. The deposited

material includes compound species that are formed due to the reaction of the solid source and the gas source, such as in the case of chemical vapor deposition. In most cases, the deposited material is then either partially or completely removed from the substrate, to form the desired product.

A first advantage of vacuum deposition processing is that vacuum deposition of the metallic and/or pseudometallic films permits tight process control and films may be deposited that have regular, homogeneous atomic and molecular pattern of distribution along their fluid-contacting surfaces. This avoids the marked variations in surface composition, creating predictable oxidation and organic adsorption patterns and has predictable interactions with water, electrolytes, proteins and cells. Particularly, EC migration is supthat serve as natural or implanted cell attachment sites, in order to promote unimpeded migration and attachment. Secondly, in addition to materials and devices that are made of a single metal or metal alloy, henceforth termed a layer, the inventive grafts may be comprised of a layer of biocompatible material or of a plurality of layers of biocompatible materials formed upon one another into a selfsupporting multilayer structure because multilayer structures are generally known to increase the mechanical strength of sheet materials, or to provide special qualities by including layers that have special properties such as superelasticity, shape memory, radio-opacity, corrosion resistance etc. A special advantage of vacuum deposition technologies is that it is possible to deposit layered materials and thus films possessing exceptional qualities may be produced (cf., H. Holleck, V. Schier: Multilayer PVD coatings for wear protection, Surface and Coatings Technology, Vol. 76-77 (1995) pp. 328-336). Layered materials, such as superstructures or multilayers, are commonly deposited to take advantage of some chemical, electronic, or optical property of the material as a coating; a common example is an antireflective coating on an optical lens. Multilayers are also used in the field of thin film fabrication to increase the mechanical properties of the thin film, specifically hardness and toughness. Thirdly, the design possibilities for possible configurations and applications of the inventive graft are greatly enhanced by employing vacuum deposition technologies. Specifically, vacuum deposition is an additive technique that lends itself toward fabrication of substantially uniformly thin materials with potentially complex three dimensional geometries and structures that cannot be cost-effectively achieved, or in some cases achieved at all, by employing conventional wrought fabrication techniques. Conventional wrought metal fabrication techniques may entail smelting, hot working, cold working, heat treatment, high temperature annealing, precipitation annealing, grinding, ablation, wet etching, dry etching, cutting and welding. All of these processing steps have disadvantages including contamination, material property degradation, ultimate achievable configurations, dimensions and tolerances, biocompatibility and cost. For example conventional wrought processes are not suitable for fabricating tubes having diameters greater than about 20 mm diameter, nor are such processes suitable for fabricating materials having wall thicknesses down to about 5  $\mu$ m with sub- $\mu$ m tolerances. While the inventive self-supporting metal or pseudometal graft may be fabricated of conventionally fabricated wrought materials, in accordance with the best mode contemplated for the present invention, the inventive graft is preferably fabricated by vacuum deposition techniques. By vacuum depositing the metal and/or pseudometallic film as

### 5

the precursor material for the inventive graft, it is possible to more stringently control the material, biocompatibility and mechanical properties of the resulting film material and graft than is possible with conventionally fabricated graftforming materials. The inventive self-supporting graft may <sup>5</sup> be used alone, i.e., the whole implantable device may be made of a single graft, or it may be a part of a structure where the graft is used in conjunction either with other grafts, or in conjunction with other structural elements, such as scaffolds, stents, and other devices. The term "in conjunction" may mean actual connection, such as that made by welding, fusing, or other joining methods, as well as being made from the same piece of material by forming some area of the piece into a graft and some other area of the piece into another member or part of the device.

### 0

For some applications it is preferable that the size of each of the plurality of microperforations be such as to permit cellular migration through each opening, without permitting fluid flow there through. In this manner, for example, blood cannot flow through the plurality of microperforations (in their deformed or un-deformed state), but various cells or proteins may freely pass through the plurality of microperforations to promote graft healing in vivo. For other applications, moderate amounts of fluid flow through the plurality of deformed or un-deformed microperforations may be acceptable. For example, endoluminal saphenous vein grafts may be fabricated with microperforations that serve the dual function of permitting transmural endothelialization while

### SUMMARY OF THE INVENTION

In accordance with a preferred embodiment of the inven-  $_{20}$ tion, there is provided a self-supporting graft member having a plurality of microperforations passing through the wall thickness of the graft. The graft member may assume virtually any geometric configuration, including sheets, tubes or rings. The plurality of microperforations may serve to impart geometric compliance to the graft, geometric distendability to the graft and/or limit or permit the passage of body fluids or biological matter through the graft, such as facilitating transmural endothelialization while preventing fluid flow through the wall of the graft under normal physiological conditions. The plurality of microperforations may also impart a fabric-like quality to the graft by imparting pliability and/or elastic, plastic or superelastic compliance to the graft, such as that required for longitudinal flexibility in the case of a vascular graft. In a first embodiment, the graft may be made from plastically deformable materials such that upon application of a force, the microperforations geometrically deform to impart permanent enlargement of one or more axes of the graft, such as length in the case of a planar graft, e.g., a  $_{40}$ surgical patch graft, or diameter, such as in the case of a tubular graft, e.g., a vascular graft. In a second embodiment, the graft may be fabricated of elastic or superelastic materials. Elastic and/or superelastic materials will permit the microperforations to geometrically deform under an applied  $_{45}$ force in a manner that allows for a recoverable change in one or more axes of the graft. In each of the first and second embodiments of the invention, the graft may be fabricated in such a manner as to have fabric-like qualities by controlling the film thick- 50 ness, material properties and geometry of the plurality of microperforations. Furthermore, in such cases where minimally invasive delivery is required, such as for endoluminal delivery of vascular grafts, the first and second embodiments allow for delivery using balloon expansion and self-expan- 5. sion, respectively, or a combination of both. Minimally invasive delivery may also be accomplished by folding the graft for delivery similar to the manner in which an angioplasty balloon is creased and fluted or folded. The graft may be delivered by unfolding the device in vivo either by 60 defining the facing surfaces of the grafts. assistance such as by using a balloon, or by the graft material's plastic, elastic or superelastic properties or by a combination thereof. After delivery, the plurality of microperforations may be patterned in such a manner as to allow for additional dimensional enlargement of the graft member by 65 elastic or plastic deformation such as a radially expansive positive pressure.

- also excluding biological debris, such as thrombus from 15 passing through the wall thickness of the graft, effectively excluding detrimental matter from entering the circulation. In this example, each of the plurality of microperforations in either their deformed or undeformed state, may exceed several hundred microns.
  - Those skilled in the art will understand that a direct relationship exists between the size of pores and the overall ratio of expansion or deformability of an implantable graft. Generally, therefore, it is appreciated that pore sizes must increase in order to increase the effective attainable degree of expansion or deformation of the graft.

For applications where large deformation and small pore size are both requirements, in accordance with another aspect of the inventive graft embodiment, it is contemplated that two or more graft members are employed such as diametrically concentric grafts for tubular configurations. The two or more graft members have a pattern of a plurality of microperforations passing there through, with the plurality of patterned microperforations being positioned out of phase relative to one another such as to create a tortuous 35 cellular migration pathway through the wall of the concentrically engaged first and second graft members as well as a smaller effective pore size. In order to facilitate cellular migration through and healing of the first and second graft members in vivo, it may be preferable to provide additional cellular migration pathways that communicate between the plurality of microperforations in the first and second graft members. These additional cellular migration pathways, if necessary, may be imparted as 1) a plurality of projections formed on either the luminal surface of the second graft or the abluminal surface of the first graft, or both, which serve as spacers and act to maintain an annular opening between the first and second graft members that permits cellular migration and cellular communication between the plurality of microperforations in the first and second graft members, 2) a plurality of microgrooves, which may be random, radial, helical, or longitudinal relative to the longitudinal axis of the first and second graft members, the plurality of microgrooves being of a sufficient size to permit cellular migration and propagation along the groove, the microgrooves serve as cellular migration conduits between the plurality of microperforations in the first and second graft members, or 3) where the microperforations are designed to impart an out of plane motion of the graft material upon deformation, thereby keeping a well defined space between the planes originally The graft member or members may be formed as a monolayer film, or may be formed from a plurality of film layers formed one upon another. The particular material used to form each layer of biocompatible metal and/or pseudometal is chosen for its biocompatibility, corrosion-fatigue resistance and mechanical properties, i.e., tensile strength, yield strength. The metals include, without limitation, the

### 7

following: titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nitinol, and stainless steel. Addition-5 ally, each layer of material used to form the graft may be doped with another material for purposes of improving properties of the material, such as radiopacity or radioactivity, by doping with tantalum, gold, or radioactive isotopes.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a perspective view of the inventive graft. FIG. 2A is a fragmentary plan view depicting a first  $_{15}$ pattern of microperforations useful in the present invention. FIG. 2B is a fragmentary plan view depicting a second pattern of microperforations useful in the present invention. FIG. 2C is a fragmentary plan view depicting a third pattern of microperforations useful in the present invention. FIG. 2D is a fragmentary plan view depicting a fourth pattern of microperforations useful in the present invention. FIG. 3A is photomicrograph depicting the inventive graft having the first pattern of microperforation depicted in FIG. 2A in a geometrically undeformed state.

### 8

ence, however, the accompanying figures and the following description of the invention will refer to tubular implantable graft members. Those skilled in the art, however, will understand that this is merely an exemplary geometric configuration and is not intended to limit the scope of the invention to tubular members or be limited in application to graft members.

With particular reference to FIG. 1, the inventive implantable medical device is illustrated as a graft 10. Graft 10 10 consists generally of a body member 12 having a first surface 14 and a second surface 16 and a thickness 18 intermediate the first surface 14 and the second surface 16. A plurality of microperforations 20 is provided and pass through the thickness 18 of the body member 12 with interperforation regions 22 of the body member 12 between adjacent microperforation 20. The plurality of microperforations 20 each preferably have a geometric configuration that is susceptible of geometric change, such that the open surface area of each microperforation 20 may change under an externally applied load. Each of the plurality of microperforations 20 in the undeformed state preferably has an open surface area less than about 2 mm<sup>2</sup>, with the total open surface area of the graft in the undeformed state being between 0.001 to 99%. The open surface area of the plurality 25 of microperforations and the open surface area of the graft may change considerably upon deformation of the plurality of microperforations 20. Both the size of the microperforations 20 in the deformed and undeformed state and the total open area of the graft 12 in the deformed and undeformed state may be selected in view of the following non-exclusive factors based on the graft application: 1) the desired compliance of the graft 10, 2) the desired strength of the graft 10, 303) desired stiffness of the graft 10, 4) the desired degree of geometric enlargement of the microperforations 20 upon FIG. 6 is a photographic illustration of the inventive graft 35 deformation and 5) in some cases, such as with vascular grafts, the desired delivery profile and post delivery profile. In accordance with a preferred embodiment of the present invention, the plurality of microperforations 20 is patterned in such a manner as to define deformation regions of the body member 12. The thickness 18 is between 0.1  $\mu$ m and 75  $\mu$ m, preferably between 1  $\mu$ m and 50  $\mu$ m. When fabricated within these thickness ranges, the graft 10 has a thickness 18 which is thinner than the wall thickness of conventional non-metallic implantable grafts and that of 45 conventional metal endoluminal stents. The plurality of microperforations is patterned in a regular array forming a regular array of microperforations 20 in both the longitudinal and circumferential axes of the body member 12. For purposes of reference, the pattern of microperforations 20 will, hereinafter, be described with reference to a planar X-Y axes, which in a tubular member will correspond to the longitudinal or circumferential axes of the tubular member. Those of ordinary skill in the art will understand that reference to X-axis or Y-axis when applied to a tubular member may be used such that the term "X-axis" may correspond to either the longitudinal axis or circumferential direction of the tubular member and the term "Y-axis" may refer to the corresponding circumferential direction or longitudinal axis or the tubular member. It will be appreciated by those of ordinary skill in the art 60 that individual different geometric patterns may have associated intended uses, function or mechanical requirements of a particular device. Thus, the particular intended use of the implantable member 12 will be a consideration in the selection of the particular geometric pattern for the plurality of microperforations 20. For example, where the implantable member 12 has an intended use as a free-standing

FIG. **3**B is a photomicrograph of the inventive graft illustrated in FIG. 3A showing the microperforations in a geometrically deformed state.

FIG. 4 is a diagrammatic illustration depicting geometric deformation of the fourth pattern of microperforations in 30 FIG. **2**D.

FIG. 5 is a diagrammatic cross-sectional view illustration depicting the inventive graft assuming a folded condition suitable for endoluminal delivery.

used as a stent covering. FIG. 7 is a photographic illustration of the inventive graft deformed approximately 180 degrees along its longitudinal axis illustrating the fabric-like quality of the graft. FIG. 8A is a photographic illustration of the inventive 40graft circumferentially covering a braided expansion member and mounted on an expansion jig that exerts a compressive force along the longitudinal axis of the braided expansion member and which radially expands the braided expansion member. FIG. 8B is a photographic illustration of the inventive graft radially exhibiting radial compliance under the influence of a radially expansive force. FIG. 9 is a flow diagram depicting alternate embodiments of making the inventive graft.

FIG. 10A is a histology slide, stained with hematoxylin and eosin, from a 28 day explanted swine carotid artery having the inventive graft implanted therein.

FIG. **10**B is a histology slide, stained with hematoxylin and eosin, from a 28 day explanted swine carotid artery 55 having the inventive graft implanted therein.

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

With the foregoing as background, we turn now to a description of the present invention with reference the preferred embodiments thereof and with reference to the accompanying figures. As noted above, the inventive microporous metallic implantable devices may assume a 65 wide number of geometric configurations, including, for example, planar sheets, tubes or toroids. For ease of refer-

### 9

implantable endoluminal vascular graft, a large circumferential expansion ratio and longitudinal flexibility may be desirable. Thus, a particular geometry of the plurality of microperforations 20 that offers these properties will be selected. The plurality of microperforations 20 also affect 5 the material properties of the implantable member 10. For example, the geometry each microperforation 20 may be altered so that each microperforation 20 exhibits stressstrain relief capabilities or the microperforations 20 may control whether geometric deformation of the microperfo- 10 rations 20 are plastic, elastic or superelastic deformation. Thus, both the geometry of the individual microperforations 20, the orientation of the microperforations 20 relative to the X-Y axis of the implantable member 10 and the pattern of the microperforations 20 may be selected to directly impart, 15 affect or control the mechanical and material properties of the implantable member 10. Different geometric patterns for the plurality of microperforations 20 in accordance with the preferred embodiments of the invention are illustrated in FIGS. 2A-2C. FIG. 20 2A illustrates a first geometry for each of the plurality of microperforations 30. In accordance with this first geometry, each of the plurality of microperforations 30 consist of generally elongated slots 32a, 32b. Each of the generally elongated slots 32a, 32b preferably include terminal fillets 25 34 on opposing ends of each elongated slot 32a, 32b. The terminal fillets 34 serve a strain relief function that aids in strain distribution through the interperforation regions 22 between adjacent slots **32**. FIG. **2**A further illustrates a first geometric pattern for the plurality of microperforations 32a, 30 32b, wherein a first row of a plurality of microperforations 32*a* is provided with adjacent microperforations 32*a* being arrayed in end-to-end fashion along a common axis, and a second row of a plurality of microperforations 32b is provided with adjacent microperforations 32b being arrayed in 35 end-to-end fashion along a common axis with one another and with the microperforations 32a. The first row of microperforations 32*a* and the second row of microperforations 32*b* are offset or staggered from one another, with an end of a microperforation 32a being laterally adjacent to an interme- 40 diate section of a microperforation 32b, and an end of microperforation 32b being laterally adjacent an intermediate section of a microperforation 32a. The first geometry 30 of the plurality of microperforations 32a, 32b illustrated in FIG. 2A permits a large deformation 45 along an axis perpendicular to a longitudinal axis of the slots. Thus, where the longitudinal axis of slots 32a, 32b is co-axial with the longitudinal axis of the implantable member 10, deformation of the slots 32a, 32b will permit circumferential compliance and/or expansion of the implant- 50 able member 10. Alternatively, where the longitudinal axis of the slots 32a, 32b is parallel to the circumferential axis of the implantable member 10, the slots 32a, 32b permit longitudinal compliance, flexibility and expansion of the implantable member 10.

### 10

the Y-axis of the implantable member 10. Like the first geometry, each of the plurality of microperforations 42a, 44b may include a terminal fillet 44 at opposing ends of the slot of each microperforation in order to serve a strain relief function and transmit strain to the interperforation region 22 between adjacent microperforations. This second geometry 40 offers a balance in both compliance and degree of expansion in both the X and Y-axes of the implantable device 12

In each of FIGS. 2A and 2B, each of the microperforations 32a, 32b, 42a, 44b has a generally longitudinal slot configuration. Each of the generally longitudinal slots may be configured as a generally linear or curvilinear slot. In accordance with the preferred embodiments of the invention, however, it is preferred to employ generally linear slots.

FIG. 2C illustrates a third preferred geometry **50** for the plurality of microperforations. In accordance with this third geometry **50**, each of the plurality of microperforations **52** has a generally trapezoidal or diamond-like shape with interperforation graft regions **56** between adjacent pairs of microperforations **52**. It will be appreciated that the third geometry **50** may be achieved by geometrically deforming the first geometry **30** along an axis perpendicular to the longitudinal axis of the plurality of microperforations **32***a*, **32***b*. Similarly, the first geometry **30** may be achieved by achieved by deforming microperforations **52** in the third geometry **50** may be achieved **50** m

FIGS. 3A and 3B are photomicrographs illustrating the inventive implantable device 12 having a plurality of microperforations formed as generally longitudinal slots 32a, 32b in accordance with the first geometry depicted in FIG. 2A. Each of the plurality of microperforations were formed with an orientation parallel to the longitudinal axis of the implantable device 12. The implantable device 12 consists of a 6 mm inner diameter NiTi shape memory tubular graft member having a wall thickness of 5 µm. FIG. 3A depicts the plurality of microperforations 32a and 32b in their undeformed state, while FIG. **3**B depicts the plurality of microperforations 32a and 32b in their geometrically deformed state under the influence of stain applied perpendicular to the longitudinal axis of the implantable graft 12. It may be clearly understood that geometric deformation of the plurality of microperforations 32a, 32b permitted circumferential expansion of the inventive graft. The dimensions of each of the plurality of microperforations in their undeformed state depicted in FIGS. 3A and 3B was 430 µm in length, 50 µm width, with the terminal fillets having a 50 µm diameter. In accordance with a fourth geometry of the plurality of microperforations 20 illustrated in FIGS. 2D and 4, each of the plurality of microperforations 20 have a generally trilegged or Y-shaped configuration. The Y-shaped configura-55 tion of each of the plurality of microperforations 20 has three co-planar radially projecting legs 31a, 31b, 31e, each offset from the other by an angle of about 120 degrees thereby forming a generally Y-shape. Each of the three co-planar radially projecting legs 31*a*, 31*b*, 31*c* may be symmetrical or asymmetrical relative to one another. However, in order to achieve uniform geometric deformation across the entire graft body member 12, it is preferable that each of the plurality of microperforations 20 has geometric symmetry. Those skilled in the art will recognize that beyond the two particular patterns described here any number of different patterns may be used without significantly departing from the inventive graft concept described in the present patent.

FIG. 2B illustrates a second geometry 40 for the plurality of microperforations 20 and consists of a plurality of microperforations 42*a*, 44*b*, again having a generally elongate slot-like configuration like those of the first geometry 30. In accordance with this second geometry 40, individual 60 microperforations 42*a* and 44*b* are oriented orthogonal relative to one another. Specifically, a first microperforation 42*a* is oriented parallel to an X-axis of the implantable member 10, while a first microperforation 44*b* is positioned adjacent to the first microperforation 44*b* is oriented perpendicular to the X-axis of the implantable member 10 and parallel to

### 11

Those skilled in the art will understand that each of the microperforations 20 are capable of undergoing deformation upon application of a sufficient force. In a tubular geometry, the graft 12 may deform both circumferentially and longitudinally. As is illustrated in FIG. 3a, each of the plurality of 5 elongated slots may deform into opened microperforations which assume a generally rhomboidal shape. Similarly, Y-shaped microperforations 20 shown in 4 are capable of deformation into generally circular or oval open microperforations 21. The deformation regions 22 between adjacent 10 microperforations 20 facilitate deformation of each of the plurality of microperforations 20 by deforming to accommodate opening of each of the plurality of microperforations **20**.

### 12

pseudometallic film may be employed at step 104. The precursor blank material obtained either from step 102 or step 104 is then preferably masked at step 108 leaving exposed only those regions defining the plurality of microperforations. The exposed regions from step 108 are then subjected to removal either by etching at step 110, such as by wet or dry chemical etching processing, with the etchant being selected based upon the material of the precursor blank, or by machining at step 112, such as by laser ablation or EDM. Alternatively, when employing the vacuum deposition step 104, a pattern mask corresponding to the plurality of microperforations may be interposed at step 106 between the target and the source and the metal or pseudometal deposited through the pattern mask to form the patterned As depicted in FIG. 5, the inventive graft 12 may be 15 microperforations. Further, when employing the vacuum deposition step 104, plural film layers maybe deposited to form a multilayer film structure of the film prior to or concurrently with forming the plurality of microperforations. Thus, the present invention provides a new metallic and/or pseudometallic implantable graft that is biocompatible, compliant, geometrically changeable either by folding and unfolding or by application of a plastically, elastically or superelastically deforming force, and, in some cases, capable of endoluminal delivery with a suitably small delivery profile and suitably low post-delivery profile. Suitable metal materials to fabricate the inventive graft are chosen for their biocompatibility, mechanical properties, i.e., tensile strength, yield strength, and in the case where vapor deposition is deployed, their ease of deposition include, without limitation, the following: titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nitinol, and stainless

folded to assume a smaller diametric profile for endoluminal delivery. In order to facilitate folding, the pattern of the plurality of microperforations 20 may be fashioned to create a plurality of folding regions 23, that constitute relatively weakened regions of the graft 12, to permit folding the graft 20 12 along folding regions 23.

FIG. 6 is a photographic illustration of the inventive microporous graft 12 circumferentially mounted onto an endoluminal stent 5. It may be readily seen that the microporous graft 12 exhibits mechanical properties of high 25 longitudinal flexibility and both radial and circumferential compliance.

FIG. 7 is a photographic illustration of the inventive microporous graft 12 mounted onto mandrel and flexed approximately 180 degrees along its longitudinal axis. Upon 30 longitudinal flexion, the inventive graft 12 undergoes a high degree of folding with a plurality of circumferentially oriented folds 7, characteristic of its fabric-like qualities.

FIGS. 8A and 8B are photographic reproductions illustrating the high degree of circumferential compliance of the 35

inventive microporous graft 12. A 6 mm microporous graft having a 5 µm wall thickness was mounted concentrically over a braided pseudostent. An axial force was applied along the longitudinal axis of the braided pseudostent causing the pseudostent to radially expand and exert a circumferentially 40 expansive force to the inventive graft 12. As is clearly depicted in FIGS. 8A and 8B the plurality of micropores in the inventive graft 12 geometrically deform thereby permitting circumferential expansion of the graft 12.

Thus, one embodiment of the present invention provides 45 a new metallic and/or pseudometallic implantable graft that is biocompatible, geometrically changeable either by folding and unfolding or by application of a plastically, elastically or superelastically deforming force, and capable of endoluminal delivery with a suitably small delivery profile. Suitable 50 metal materials to fabricate the inventive graft are chosen for their biocompatibility, mechanical properties, i.e., tensile strength, yield strength, and their ease of fabrication. The compliant nature of the inventive graft material may be employed to form the graft into complex shapes by deform- 55 ing the inventive graft over a mandrel or fixture of the appropriate design. Plastic deformation and shape setting heat treatments may be employed to ensure the inventive implantable members 10 retain a desired conformation. According to a first preferred method of making the graft 60 of the present invention, the graft is fabricated of vacuum deposited metallic and/or pseudometallic films. With particular reference to FIG. 9, the fabrication method 100 of the present invention is illustrated. A precursor blank of a conventionally fabricated biocompatible metal or pseudo- 65 metallic material may be employed at step 102. Alternatively, a precursor blank of a vacuum deposited metal or

steel. Examples of pseudometallic materials potentially useful with the present invention include, for example, composite materials and ceramics.

The present invention also provides a method of making the inventive expandable metallic graft by vacuum deposition of a graft-forming metal or pseudometal and formation of the microperforations either by removing sections of deposited material, such as by etching, EDM, ablation, or other similar methods, or by interposing a pattern mask, corresponding to the microperforations, between the target and the source during deposition processing. Alternatively, a pre-existing metal and/or pseudometallic film manufactured by conventional non-vacuum deposition methodologies, such as wrought hypotube or sheet, may be obtained, and the microperforations formed in the pre-existing metal and/or pseudometallic film by removing sections of the film, such as by etching, EDM, ablation, or other similar methods. An advantage of employing multilayer film structures to form the inventive graft is that differential functionalities may be imparted in the discrete layers. For example, a radiopaque material such as tantalum may form one layer of a structure while other layers are chosen to provide the graft with its desired mechanical and structural properties. In accordance with the preferred embodiment of fabricating the inventive microporous metallic implantable device in which the device is fabricated from vacuum deposited nitinol tube, a cylindrical deoxygenated copper substrate is provided. The substrate is mechanically and/or electropolished to provide a substantially uniform surface topography for accommodating metal deposition thereupon. A cylindrical hollow cathode magnetron sputtering deposition device was employed, in which the cathode was on the outside and

### 13

the substrate was positioned along the longitudinal axis of the cathode. A cylindrical target consisting either of a nickel-titanium alloy having an atomic ratio of nickel to titanium of about 50-50% and which can be adjusted by spot welding nickel or titanium wires to the target, or a nickel 5 cylinder having a plurality of titanium strips spot welded to the inner surface of the nickel cylinder, or a titanium cylinder having a plurality of nickel strips spot welded to the inner surface of the titanium cylinder is provided. It is known in the sputter deposition arts to cool a target within 10 the deposition chamber by maintaining a thermal contact between the target and a cooling jacket within the cathode. In accordance with the present invention, it has been found useful to reduce the thermal cooling by thermally insulating the target from the cooling jacket within the cathode while 15 still providing electrical contact to it. By insulating the target from the cooling jacket, the target is allowed to become hot within the reaction chamber. Two methods of thermally isolating the cylindrical target from the cooling jacket of the cathode were employed. First, a plurality of wires having a 20 diameter of 0.0381 mm were spot welded around the outer circumference of the target to provide an equivalent spacing between the target and the cathode cooling jacket. Second, a tubular ceramic insulating sleeve was interposed between the outer circumference of the target and the cathode cooling 25 jacket. Further, because the Ni—Ti sputtering yields can be dependent on target temperature, methods which allow the target to become uniformly hot are preferred. The deposition chamber was evacuated to a pressure less than or about  $2-5 \times 10^{-7}$  Torr and pre-cleaning of the substrate 30 is conducted under vacuum. During the deposition, substrate temperature is preferably maintained within the range of 300 and 700 degrees Centigrade. It is preferable to apply a negative bias voltage between 0 and -1000 volts to the substrate, and preferably between –50 and –150 volts, which 35 is sufficient to cause energetic species arriving at the surface of the substrate. During deposition, the gas pressure is maintained between 0.1 and 40 mTorr but preferably between 1 and 20 mTorr. Sputtering preferably occurs in the presence of an Argon atmosphere. The argon gas must be of 40 high purity and special pumps may be employed to reduce oxygen partial pressure. Deposition times will vary depending upon the desired thickness of the deposited tubular film. After deposition, the plurality of microperforations are formed in the tube by removing regions of the deposited film 45 by etching, such as chemical etching, ablation, such as by excimer laser or by electric discharge machining (EDM), or the like. After the plurality of microperforations are formed, the formed microporous film is removed from the copper substrate by exposing the substrate and film to a nitric acid 50 bath for a period of time sufficient to remove dissolve the copper substrate.

### 14

proliferation with the absence of trauma to the internal elastic lamina. FIG. **10**B is a sample indicating cross-talk between the arterial superficial and deep layers with the transmural formation of small capillaries.

While the present invention has been described with reference to its preferred embodiments, those of ordinary skill in the art will understand and appreciate that variations in materials, dimensions, geometries, and fabrication methods may be or become known in the art, yet still remain within the scope of the present invention which is limited only by the claims appended hereto.

### What is claimed is:

**1**. An implantable medical graft, comprising: a. a tubular graft member comprising a vacuum deposited metal film having a first surface, a second surface and a thickness intermediate the first surface and the second surface wherein said thickness is less than 75 µm; and b. a plurality of microperforations formed in and passing through the thickness of the vacuum deposited metal film and communicating between the first surface and the second surface. 2. The implantable medical graft according to claim 1, wherein the vacuum deposited metal film is made of a metallic material selected from the group consisting of titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof.

**3**. The implantable graft according to claim **1**, wherein the each of the plurality of microperforations is capable of undergoing geometric deformation.

4. The implantable graft according to claim 1, wherein the plurality of microperforations are arrayed in at least one pattern that imparts at least one of compliance and pliability to the body member.

### EXAMPLE

A 5 µm thick NiTi graft having a pattern of microperforations consisting of parallel staggered longitudinally oriented linear slots, each slot being 430 µm length, 25 µm width, and having 50 µm diameter fillets on each end of each linear slot, was mounted onto a 6 mm NiTi stent and 60 delivered endoluminally to the left carotid artery of a swine. After 28 days, the swine was euthanized, and the graft explanted from the left carotid artery. Samples were prepared using standard hematoxylin and eosin staining procedures, and microscope slides prepared. As illustrated in FIG. 65 10A histology of the explanted samples revealed complete endothelialization around the graft 12, negligible neointimal

5. The implantable graft according to claim 1, wherein the plurality of microperforations is arrayed in at least one pattern sufficient to permit dimensional change of at least a portion of the device.

6. The implantable graft according to claim 5, wherein the dimensional change comprises at elastic one of elastic, plastic, shape memory and superelastic compliance.

7. The implantable medical graft according to claim 1, wherein the tubular graft member further comprises a first surface including a luminal surface and a second surface including an abluminal surface.

**8**. The implantable medical graft according to claim **1**, wherein the tubular graft member further comprises a generally planar member.

**9**. The implantable medical graft according to claim **1**, wherein the plurality of microperforations each further comprise a generally co-planar tri-leg configuration.

**10**. An implantable medical device, comprising a gener-55 ally tubular, non-coiled, graft member consisting essentially of:

a. a vacuum deposited metal film having a first surface, a second surface and a thickness intermediate the first surface and the second surface wherein said thickness is less than 75 µm; and
b. a plurality of microperforations formed in and passing through the thickness of the vacuum deposited metal film and communication between the first surface and the second surface, each of the plurality of microperforations having an open surface area less than about 2 mm<sup>2</sup> when the graft member is in a non-diametrically

enlarged state.

### 15

11. The implantable medical graft according to claim 10, wherein the vacuum deposited metal film is made of a metallic material selected from the group consisting of titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scan- 5 dium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof.

**12**. The implantable graft according to claim **10**, wherein the each of the plurality of microperforations is capable of undergoing geometric deformation.

**13**. The implantable graft according to claim **10**, wherein erally planar member. the plurality of microperforations are arrayed in at least one pattern that imparts at least one of compliance and pliability wherein the plurality of microperforations each further comto the body member.

### 16

15. The implantable graft according to claim 14, wherein the dimensional change comprises at elastic one of elastic, plastic, shape memory and superelastic compliance.

16. The implantable medical graft according to claim 10, wherein the tubular graft member further comprises a first surface including a luminal surface and a second surface including an abluminal surface.

17. The implantable medical graft according to claim 10, <sup>10</sup> wherein the tubular graft member further comprises a gen-

18. The implantable medical graft according to claim 10,

14. The implantable graft according to claim 10, wherein 15 prise a generally co-planar tri-leg configuration. the plurality of microperforations is arrayed in at least one pattern sufficient to permit dimensional change of at least a portion of the device.